Table 1.
Recipient baseline characteristics stratified by donor brain death duration
| Time from brain death to cross clamp | ||||
|---|---|---|---|---|
| Variable | < 22 hours | 22–42 hours | > 42 hours | p-value |
| (n=2,112) | (n=12,621) | (n=8,227) | ||
| Male gender | 78.6% (1,660) | 74.5% (9,400) | 73.9% (6,079) | < 0.001 |
| Age (median, IQR) | 55 (16) | 56 (16) | 57 (16) | < 0.001 |
| BMI | 27.1 (7.1) | 27.1 (6.9) | 26.9 (6.9) | 0.224 |
| Ethnicity | < 0.001 | |||
| White | 70.4% (1,487) | 68.1% (8,594) | 64.5% (5,308) | |
| Black | 19.4% (410) | 21.1% (2,660) | 20.3% (1,668) | |
| Hispanic | 6.9% (145) | 7.2% (904) | 9.6% (789) | |
| Other | 3.3% (70) | 3.7% (463) | 5.6% (462) | |
| Recipient history | ||||
| Diabetes | 30.3% (639) | 27.6% (3,488) | 26.6% (2,186) | 0.003 |
| Malignancy | 7.1% (151) | 7.6% (955) | 8.2% (672) | 0.159 |
| Cerebrovascular disease | 5.4% (114) | 5.6% (701) | 5.3% (439) | 0.788 |
| Recipient heart failure etiology | < 0.001 | |||
| Ischemic | 37.4% (790) | 34.5% (4,351) | 31.1% (2,562) | |
| Non-ischemic dilated | 47.1% (995) | 50.2% (6,330) | 52.3% (4306) | |
| Other | 15.5% (327) | 15.4% (1,940) | 16.5% (1,359) | |
| Recipient creatinine (median, IQR) | 1.2 (0.5) | 1.2 (0.5) | 1.2 (0.5) | < 0.001 |
| Recipient bilirubin (median, IQR) | 0.8 (0.7) | 0.8 (0.7) | 0.7 (0.6) | < 0.001 |
| Pre-transplant status | 0.039 | |||
| Intensive care unit | 30.3% (639) | 28.5% (3,595) | 28.0% (2,305) | |
| Hospitalized (non-ICU) | 16.8% (354) | 15.2% (1,922) | 15.9% (1,311) | |
| Not hospitalized | 53.0% (1,119) | 56.3% (7,104) | 56.0% (4,611) | |
| Medical therapy | ||||
| IV antibiotics in two weeks before transplant | 9.8% (208) | 10.6% (1,343) | 9.7% (796) | 0.067 |
| IV inotropes prior to transplant | 45.9% (970) | 39.1% (4,939) | 35.6% (2,925) | < 0.001 |
| Ventilator support prior to transplant | 2.0% (42) | 1.6% (201) | 0.9% (74) | < 0.001 |
| IABP prior to transplant | 6.5% (137) | 6.2% (784) | 5.7% (467) | 0.191 |
| ECMO support prior to transplant | 0.8% (16) | 0.6% (72) | 0.5% (45) | 0.514 |
| VAD prior to transplant | 34.7% (732) | 40.6% (5,127) | 46.4% (3,818) | < 0.001 |
| ABO blood type | 0.008 | |||
| A | 43.8% (926) | 40.9% (5,168) | 39.6% (3,257) | |
| B | 14.0% (295) | 14.3% (1,809) | 15.2% (1,247) | |
| AB | 4.9% (103) | 5.9% (749) | 5.6% (459) | |
| O | 37.3% (788) | 38.8% (4,895) | 39.7% (3,264) | |
| Days on waitlist (median, IQR) | 76 (189) | 92 (226) | 100 (264) | < 0.001 |
| Waitlist status at transplant | < 0.001 | |||
| 1A | 55.4% (1,170) | 57.3% (7,238) | 62.5% (5,141) | |
| 1B | 37.6% (794) | 36.5% (4,602) | 31.4% (2,584) | |
| 2 | 7.0% (148) | 6.2% (780) | 6.1% (502) | |
| Year of transplant (median, IQR) | 2009 (5) | 2011 (5) | 2015 (4) | < 0.001 |
| Acute rejection prior to discharge | 18.3% (386) | 18.7% (2,357) | 18.3% (1,503) | 0.734 |
| Treated for rejection within 1 year* | 24.3% (432) | 21.2% (2,170) | 18.3% (1,043) | < 0.001 |
*
of transplants performed prior to 2017; IQR, interquartile range; BMI, body mass index; ICU, intensive care unit; IABP, intra-aortic balloon pump; ECMO, extracorporeal membrane oxygenation; VAD, ventricular assist device